These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9195561)

  • 21. Interleukin-1 stimulates the expression of type I and type II interleukin-1 receptors in the rat insulinoma cell line Rinm5F; sequencing a rat type II interleukin-1 receptor cDNA.
    Bristulf J; Gatti S; Malinowsky D; Bjork L; Sundgren AK; Bartfai T
    Eur Cytokine Netw; 1994; 5(3):319-30. PubMed ID: 7524717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A; Cameron RB; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness.
    Kunz M; Hartmann A; Flory E; Toksoy A; Koczan D; Thiesen HJ; Mukaida N; Neumann M; Rapp UR; Bröcker EB; Gillitzer R
    Am J Pathol; 1999 Sep; 155(3):753-63. PubMed ID: 10487833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction.
    Satyamoorthy K; Li G; Vaidya B; Kalabis J; Herlyn M
    Cell Growth Differ; 2002 Feb; 13(2):87-93. PubMed ID: 11864912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3).
    Tsuji T; Kawada Y; Kai-Murozono M; Komatsu S; Han SA; Takeuchi K; Mizushima H; Miyazaki K; Irimura T
    Clin Exp Metastasis; 2002; 19(2):127-34. PubMed ID: 11964076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1 beta suppresses apoptosis in CD34 positive bone marrow cells through activation of the type I IL-1 receptor.
    Rodriguez C; Lacasse C; Hoang T
    J Cell Physiol; 1996 Feb; 166(2):387-96. PubMed ID: 8591999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-4 and IL-13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression.
    Etter H; Althaus R; Eugster HP; Santamaria-Babi LF; Weber L; Moser R
    Cytokine; 1998 Jun; 10(6):395-403. PubMed ID: 9632524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An antibody to a 17 amino acid synthetic peptide of the type I interleukin-1 receptor preferentially blocks interleukin-1 beta binding.
    Clark BD; Ikejima T; Mancilla J; Orencole SF; Sirko SP; Ishii N; Okuda K; Dinarello CA
    J Interferon Cytokine Res; 1996 Dec; 16(12):1079-88. PubMed ID: 8974012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor.
    Garrone P; Djossou O; Fossiez F; Reyes J; Ait-Yahia S; Maat C; Ho S; Hauser T; Dayer JM; Greffe J; Miossec P; Lebecque S; Rousset F; Banchereau J
    Mol Immunol; 1996; 33(7-8):649-58. PubMed ID: 8760277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of melanoma cell motility factor receptor expression by retinoic acid.
    Lotan R; Amos B; Watanabe H; Raz A
    Cancer Res; 1992 Sep; 52(18):4878-84. PubMed ID: 1325286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
    McIntyre KW; Stepan GJ; Kolinsky KD; Benjamin WR; Plocinski JM; Kaffka KL; Campen CA; Chizzonite RA; Kilian PL
    J Exp Med; 1991 Apr; 173(4):931-9. PubMed ID: 1826128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases.
    Garofalo A; Chirivi RG; Foglieni C; Pigott R; Mortarini R; Martin-Padura I; Anichini A; Gearing AJ; Sanchez-Madrid F; Dejana E
    Cancer Res; 1995 Jan; 55(2):414-9. PubMed ID: 7529137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.
    Jen EY; Poindexter NJ; Farnsworth ES; Grimm EA
    Melanoma Res; 2012 Feb; 22(1):19-29. PubMed ID: 22027907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respective effects of soluble interleukin-1 receptor and tumour necrosis factor receptor on IL-1 and TNF-alpha-induced DNA synthesis of common acute lymphoblastic leukaemia blasts in vitro.
    Carter A; Haddad N; Draxler I; Israeli E; Raz B; Tatarsky I
    Br J Haematol; 1994 Jan; 86(1):22-9. PubMed ID: 8011537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-1 alpha, but not interleukin-1 beta, is a co-mitogen for neonatal rat Schwann cells in vitro and acts via interleukin-1 receptors.
    Lisak RP; Bealmear B; Ragheb S
    J Neuroimmunol; 1994 Dec; 55(2):171-7. PubMed ID: 7829667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of type I and type II interleukin-1 receptors in mouse brain.
    Parnet P; Amindari S; Wu C; Brunke-Reese D; Goujon E; Weyhenmeyer JA; Dantzer R; Kelley KW
    Brain Res Mol Brain Res; 1994 Nov; 27(1):63-70. PubMed ID: 7877456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.
    Poli G; Kinter AL; Fauci AS
    Proc Natl Acad Sci U S A; 1994 Jan; 91(1):108-12. PubMed ID: 7506410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions.
    Goldbrunner RH; Haugland HK; Klein CE; Kerkau S; Roosen K; Tonn JC
    Anticancer Res; 1996; 16(6B):3679-87. PubMed ID: 9042241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that the interleukin-1 beta-induced prostaglandin E2 release from rat hypothalamus is mediated by type I and type II interleukin-1 receptors.
    Mirtella A; Tringali G; Guerriero G; Ghiara P; Parente L; Preziosi P; Navarra P
    J Neuroimmunol; 1995 Sep; 61(2):171-7. PubMed ID: 7593552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.